Compound News and Research

RSS

Lilly, QIAGEN partner to develop and commercialize companion diagnostic for JAK2 V617F

QIAGEN today announced that it has entered into a partnership with Eli Lilly and Company for the development, manufacturing and commercialization of a molecular companion diagnostic for an early stage investigational compound currently being developed by Lilly. Financial terms of the agreement were not disclosed.

From QIAGEN Manchester Limited 6 Sep 2011

Gilead to amend design of ongoing clinical trials against chronic hepatitis C

Gilead Sciences, Inc. today announced that, in consultation with the U.S. Food and Drug Administration (FDA), the company will amend the design of ongoing clinical trials to discontinue dosing of GS 9190 in hepatitis C-infected patients who are receiving that compound in combination with pegylated interferon and ribavirin, and another direct-acting antiviral agent.

5 Sep 2011

Study describes new class of anti-diabetic compound that targets unique molecular switch

In a joint study, scientists from The Scripps Research Institute and Harvard University's Dana-Farber Cancer Institute have established a new class of anti-diabetic compound that targets a unique molecular switch.

5 Sep 2011

Researchers modify toxic chemical of marine cycyanobacteria to treat colon cancer

University of Florida researchers have modified a toxic chemical produced by tiny marine microbes and successfully deployed it against laboratory models of colon cancer.

2 Sep 2011

One third of patients with unexplained body malodor production test positive for TMAU

Scientists from the Monell Center report that approximately one third of patients with unexplained body malodor production test positive for the metabolic disorder trimethylaminuria.

2 Sep 2011

Sunscreen pills from coral

Researchers have found that coral does not suffer from sunburn despite living in shallow water in tropical areas, because it is able to produce its own “natural sunscreen”. By studying the compounds which protect it from UV rays, researchers hope to develop a tablet which can protect human skin and eyes without the need for dark glasses or sun cream. Scientists from King's College London said the first sunscreen pill could be available within five years.

31 Aug 2011

Eisai announces results of perampanel Phase III study on epilepsy

Results presented today of a Phase III pivotal study for the investigational compound perampanel for partial-onset seizures showed that perampanel, 8 mg and 12 mg, produced statistically significant reductions in median seizure frequency compared to placebo among patients having partial-onset seizures while receiving treatment with one to three other epilepsy drugs.

31 Aug 2011

Medivir reports net sales of SEK 444.6 m for 1 January - 30 June 2011

Medivir: Interim period (January 2011 - June 2011). Net sales were SEK 444.6 (35.7) m.

31 Aug 2011

Comprehensive review on non-drug interventions for treatment of high blood pressure

More and more, patients show up to appointments with hypertension expert John Bisognano, M.D., Ph.D. carrying bags full of "natural" products that they hope will help lower their blood pressure. And like most physicians, Bisognano doesn't always know if these products will do any good, or if they will cause any harm.

31 Aug 2011

Enrollment commences in Adamis' APC-100 Phase 1/2a clinical prostate study

Adamis Pharmaceuticals Corporation announced today that it enrolled the first patient in its Phase 1/2a clinical prostate study. Adamis' drug, APC-100, will be used to treat men with castrate-resistant prostate cancer.

31 Aug 2011

Results of Aeterna Zentaris' AEZS-131 anticancer Erk inhibitor presented at ACS 2011 meeting

Aeterna Zentaris Inc. today announced that a poster on its novel orally active anticancer Erk inhibitor, which includes AEZS-131, was presented at the 242nd American Chemical Society National Meeting held at the Colorado Convention Center in Denver, Colorado.

30 Aug 2011

EMD Millipore acquires Amnis

Amnis Corporation, a manufacturer of advanced cell imaging systems, today announced that the company has been acquired by EMD Millipore, the Life Science division of Merck KGaA of Germany.

30 Aug 2011

DNA sequencing pioneer, two pharmaceutical researchers recognized as ACS 'Heroes of Chemistry'

Two scientists developed a new drug that helped pioneer the era of "personalized medicine" for cancer patients, an approach in which one-size-fits-all drugs yield to medicines customized to the genetic endowment of individual patients. Another scientist invented today's predominant technology for genetic sequencing, deciphering the genetic blueprint in the DNA that makes up the genes of living things.

30 Aug 2011

Ecstasy redesigned for use against blood cancer

The illicit drug ecstasy has been redesigned by researchers at the University of WA for use in treatment of blood cancers.

30 Aug 2011

Curemark's novel compound CM-182 shows promise for treatment of hyperactivity without sedation

Curemark, LLC, a drug research and development company focused on the treatment of neurological diseases, announced today that its compound CM-182 demonstrated positive results for reduction in hyperactivity in mice treated with amphetamines. The mouse model screening was performed by the contract research organization, Cerca Insights.

29 Aug 2011

Boehringer Ingelheim initiates two afatinib phase II studies in HER2-positive breast cancer

Boehringer Ingelheim today announced the initiation of two phase II studies, 1200.89 and LUX-Breast 2, evaluating afatinib in patients with metastatic breast cancer, who have an overexpression of the erbB2 (HER2) protein, so called HER2-positive patients. Afatinib is an irreversible ErbB Family Blocker, which binds to all erbB-family kinases including erbB2.

29 Aug 2011

Protein that allows Ebola virus to attack cells discovered

A U.S. research team has discovered a protein called Niemann-Pick C1 (NPC1), which they found was responsible for allowing Ebola virus to enter and replicate within cells.

26 Aug 2011

Yale scientists synthesize huperzine A to combat Alzheimer's

Scientists at Yale University have developed the first practical method to create a compound called huperzine A in the lab.

26 Aug 2011

Emergent announces results of adjuvanted BioThrax anthrax vaccine Phase 1a trial

Emergent BioSolutions Inc. announced today that results from a Phase 1a clinical trial evaluating an investigational anthrax vaccine, Anthrax Vaccine Adsorbed with CPG 7909 Adjuvant mixed at bedside, have been published in Vaccine, a leading medical journal on vaccines and immunology.

26 Aug 2011

MDxHealth first half 2011 commercial revenues increase 19%

MDxHealth SA, a leading molecular diagnostics company in the field of personalized medicine, announced today its 2011 half-year results.

25 Aug 2011

Compound News and Research

Lilly, QIAGEN partner to develop and commercialize companion diagnostic for JAK2 V617F

Gilead to amend design of ongoing clinical trials against chronic hepatitis C

Study describes new class of anti-diabetic compound that targets unique molecular switch

Researchers modify toxic chemical of marine cycyanobacteria to treat colon cancer

One third of patients with unexplained body malodor production test positive for TMAU

Sunscreen pills from coral

Eisai announces results of perampanel Phase III study on epilepsy

Medivir reports net sales of SEK 444.6 m for 1 January - 30 June 2011

Comprehensive review on non-drug interventions for treatment of high blood pressure

Enrollment commences in Adamis' APC-100 Phase 1/2a clinical prostate study

Results of Aeterna Zentaris' AEZS-131 anticancer Erk inhibitor presented at ACS 2011 meeting

EMD Millipore acquires Amnis

DNA sequencing pioneer, two pharmaceutical researchers recognized as ACS 'Heroes of Chemistry'

Ecstasy redesigned for use against blood cancer

Curemark's novel compound CM-182 shows promise for treatment of hyperactivity without sedation

Boehringer Ingelheim initiates two afatinib phase II studies in HER2-positive breast cancer

Protein that allows Ebola virus to attack cells discovered

Yale scientists synthesize huperzine A to combat Alzheimer's

Emergent announces results of adjuvanted BioThrax anthrax vaccine Phase 1a trial

MDxHealth first half 2011 commercial revenues increase 19%

Enhancing confidence in chemical ionization spectrometry data eBook

Improving healthcare sustainability through carbon data

A New Approach to Preventing Bladder Cancer Recurrence

Bringing real-time analytics to downstream bioprocess monitoring

Latest News